
Haemonetics Corporation (HAE)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
60.09 - Open
60.30 - Bid --
- Ask --
- Day's Range
59.24 - 60.72 - 52 Week Range
47.32 - 87.32 - Volume
618,682 - Avg. Volume
809,686 - Market Cap (intraday)
2.754B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
16.33 - EPS (TTM)
3.63 - Earnings Date May 7, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
84.60
Recent News: HAE
View MorePerformance Overview: HAE
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends: HAE
View MoreAnalyst Insights: HAE
View MoreStatistics: HAE
View MoreValuation Measures
-
Market Cap
2.75B
-
Enterprise Value
3.62B
-
Trailing P/E
16.33
-
Forward P/E
10.87
-
PEG Ratio (5yr expected)
0.91
-
Price/Sales (ttm)
2.16
-
Price/Book (mrq)
3.02
-
Enterprise Value/Revenue
2.74
-
Enterprise Value/EBITDA
9.94
Financial Highlights
Profitability and Income Statement
-
Profit Margin
13.31%
-
Return on Assets (ttm)
6.45%
-
Return on Equity (ttm)
19.30%
-
Revenue (ttm)
1.32B
-
Net Income Avi to Common (ttm)
175.44M
-
Diluted EPS (ttm)
3.63
Balance Sheet and Cash Flow
-
Total Cash (mrq)
363.56M
-
Total Debt/Equity (mrq)
134.40%
-
Levered Free Cash Flow (ttm)
335.05M
Compare To: HAE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: HAE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: HAE
View More-
What does Argus have to say about HAE?
Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Lowering target price to $66.00
Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $67.00
Haemonetics Corp has an Investment Rating of BUY; a target price of $67.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $66.00
Haemonetics Corp has an Investment Rating of BUY; a target price of $66.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target






